Navigation Links
Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
Date:3/9/2010

nd Government Affairs, Preston Klassen, M.D., MHS as Head of the Global Contrave Program and Whedy Wang, Ph.D., MPH as Head of Global Biomedical Information.  

Contrave

Orexigen announced the results of all four of its Phase 3 trials in the Contrave Obesity Research, or COR, program in 2009.  Each trial met its co-primary endpoints. Data from these trials demonstrated the following:

  • In the COR-I and COR-II trials, approximately 48% and 56% of patients on Contrave32 lost at least 5% of their body weight after 56 weeks on an intent-to-treat basis, as compared to placebo patients who lost approximately 16% and 17% (p<0.001).  Additionally, approximately 34% to 48% of patients who completed one year of therapy on Contrave32 in these two trials lost at least 10% of their baseline body weight.
  • In the COR-BMOD trial, which incorporated an intensive diet and exercise behavior modification regimen, approximately 55% of patients who completed one year of therapy on Contrave32 lost at least 10% of their baseline body weight.
  • In the COR-Diabetes trial, patients with type 2 diabetes taking Contrave lost significantly mor
    '/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and KISSING, Germany , July 30, ... a single use and computer-assisted ("robotic") colonoscopy system, today ... a worldwide recognized medical device executive, as a new ... Shamir is a highly respected global visionary in the ... served as President and Chief Executive Officer at Given ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... , , SAN DIEGO , Jan. 15 ... entry of a settlement agreement which will resolve the consolidated securities ... Master File No: 3:09-cv-00921-LAB-WMC. The defendants have agreed to pay ... the company has agreed to issue to the plaintiffs, class a ...
... , , , , , , ... Jan. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China ... a,leading fully integrated pharmaceutical company developing and producing,over-the-counter drugs in ... the Company has relocated its headquarters to its new buildings,in ...
Cached Medicine Technology:Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 2Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 3Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 4China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters 2China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters 3
(Date:7/30/2014)... The Technology Association of Georgia in collaboration ... today issued its final call for applications and nominations ... have until August 29th 2014 to be considered for ... by the Excalibur Judging Committee. Companies selected as semi-finalists ... for interviewing process. , The TAG Excalibur Awards ...
(Date:7/30/2014)... The American Telemedicine Association (ATA) today ... (R-MS) and Roger Wicker (R-MS) for their efforts ... Medicare, Medicaid and Federal Communications Commission programs. , ... the Telehealth Enhancement Act as S. 2662, a ... introduced by Rep. Gregg Harper (R-MS) which already ...
(Date:7/30/2014)... 2014 Deep Research Report ... a professional and in-depth research report on ... basic Chitosan information, including Chitosan definition, classification, ... as industry overview. This research covers international ... well as global industry analysis covering macroeconomic ...
(Date:7/30/2014)... --,Although the vast majority of kids with autism have ... differently from children who have trouble processing sensory stimuli, ... can be overly sensitive to sound, sight and touch. ... a lack of concentration. Complicating matters, some kids ... have trouble tolerating loud noises, like a vacuum. Others ...
(Date:7/30/2014)... 30, 2014 Everyone knows that the internet ... everyone. Whether people are looking for something to buy, trying ... dentist, the internet is pretty much always going to be ... in Lauderdale Florida is so happy to announce the launch ... presence into the modern age. Whether a person wants to ...
Breaking Medicine News(10 mins):Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 3Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2
... A study by researchers at UC Davis has found that ... to produce autoantibodies to the brains of their developing fetuses ... risk of later being diagnosed with autism. The finding ... in the development of the neurodevelopmental disorder among some children ...
... Canadian Journal of Cardiology ( www.onlinecjc.ca ) ... imaging methods. This study is important for patients worried ... heart. X-ray based methods have greatly improved the diagnosis ... of radiation exposure. New imaging methods offer ...
... Serena Gordon HealthDay Reporter , TUESDAY, Oct. ... the way that parts of kidney dialysis machines are ... A recently developed sterilization method called electron ... platelets in the blood of dialysis patients, according to ...
... online Oct. 18 in the Journal of the National ... the idea that the immune system,s response to allergies may ... with somewhat elevated blood levels of immunoglobulin E (IgE), antibodies ... significantly less likely to develop gliomas, and those who did ...
... Ind. -- A new study by researchers at Indiana University ... men surprisingly diverse, suggesting that a broader, less disease-focused perspective ... addressing the sexual health of gay and bisexual men. ... Journal of Sexual Medicine, tapped the largest sample ...
... population will nearly double by 2050, according to a ... exists as to who will care for them as ... but those caregiving roles are becoming blurred as more ... previous decades. Now, University of Missouri researchers have found ...
Cached Medicine News:Health News:Genetic variant and autoantibodies linked to having a child with autism 2Health News:Genetic variant and autoantibodies linked to having a child with autism 3Health News:Genetic variant and autoantibodies linked to having a child with autism 4Health News:Study Links New Dialysis Technology to Rise in Bleeding Risk 2Health News:Study Links New Dialysis Technology to Rise in Bleeding Risk 3Health News:More evidence that allergies may help in fighting brain tumors 2Health News:New study finds gay and bisexual men have varied sexual repertoires 2Health News:New study finds gay and bisexual men have varied sexual repertoires 3Health News:Relationships more important than genetic ties when deciding who cares for aging family, study finds 2
... LMA ™ Airway., ,The LMA ... which allows it to be positioned ... maintaining a good seal. This makes ... dental surgery, or other procedures where ...
... The Intubating LMA™ Airway. , ... or unexpected difficult airway, the LMA Fastrach™ ... without moving the head or neck. The ... attempts. , ,Selected by emergency teams ...
... Most Versatile LMA™ Airway., ,The LMA ... The double cuff design enables seal pressures ... achieved. The drain tube separates the alimentary ... the flexible airway tube, enable longer periods ...
... As experts in the ... Portex can offer an integrated ... management requirements. The single-use Portex ... an important addition to this ...
Medicine Products: